The 21-gene recurrence score in male breast cancer Journal Article
| Authors: | Turashvili, G.; Gonzalez-Loperena, M.; Brogi, E.; Dickler, M.; Norton, L.; Morrow, M.; Wen, H. Y. |
| Article Title: | The 21-gene recurrence score in male breast cancer |
| Abstract: | Background: Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER+/HER2− female breast cancer. We assessed the association between RS and type of treatment in male breast cancer. Methods: We identified male patients with ER+/HER2− breast cancer and available RS results treated at our institution in 2006–2016. We collected data on clinicopathologic features, treatment, and outcome. The Institutional Review Board approved the study. Results: The study cohort consists of 38 male breast cancer patients with a median age of 70 years. Median tumor size was 1.6 cm, and 81.6% (31) were node-negative. RS was low (≤ 17) in 26 (68.4%) cases, intermediate (18–30) in 9 (23.7%) cases, and high (≥ 31) in 3 (7.9%) cases, comparable to that in female patients at our institution. All patients underwent total mastectomy, and one received radiotherapy. Thirty-four (89.5%) patients received adjuvant endocrine therapy, mostly tamoxifen (81.6%; 31). Five (13.2%) patients with intermediate or high RS were treated with adjuvant chemotherapy. No locoregional recurrence was observed, and one patient developed distant recurrence (median follow-up 34 months). Conclusions: The RS distribution in male breast cancers was similar to that in females treated at our institution. With limited follow-up, patients with low RS were spared chemotherapy and did not develop recurrence. Our results suggest that the RS may have a clinical utility in male breast cancer patients. © 2018, Society of Surgical Oncology. |
| Keywords: | adult; clinical article; treatment outcome; aged; middle aged; cancer surgery; clinical feature; cancer recurrence; drug withdrawal; unspecified side effect; cancer adjuvant therapy; cancer patient; cancer radiotherapy; recurrence risk; follow up; lymph node metastasis; cancer grading; reverse transcription polymerase chain reaction; tumor volume; epidermal growth factor receptor 2; aromatase inhibitor; cohort analysis; brca1 protein; brca2 protein; retrospective study; distant metastasis; cancer hormone therapy; scoring system; tamoxifen; invasive carcinoma; papillary carcinoma; estrogen receptor; progesterone receptor; intraductal carcinoma; male breast cancer; institutional review; germline mutation; estrogen receptor positive breast cancer; apocrine carcinoma; human; male; article; simple mastectomy; progesterone receptor positive breast cancer; 21 gene recurrence score |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 25 |
| Issue: | 6 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2018-06-01 |
| Start Page: | 1530 |
| End Page: | 1535 |
| Language: | English |
| DOI: | 10.1245/s10434-018-6411-z |
| PROVIDER: | scopus |
| PMCID: | PMC5930124 |
| PUBMED: | 29520654 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work